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 الرسالة ملخص
 شــــــــًـــــــس  انـــذٌٍ عــــــبـــــذانهـــّ ْــــــهــــذٔ:  الاســـــــــــــــم
 .اث انتأثٍش انحٍٕيذانتصٍُع انتكبيهً  نهًُتجبث انطبٍعٍت :  الرسالة عنوان
 انكٍـــًٍـــبء:  التخصــــــــص
 2020ٌٍَٕٕ :    تاريخ التخرج
                                                                         
انًُتجبث انطبٍعٍت انبحشٌت ،  spermpeimrmsneٔفً انذساست انحبنٍت تى إَجبص تشكٍب يجًٕع 
 -  أنف ، يثبظ  aaeeaaelmsnelانًبَع ، ٔ) irrt(انكشبٕكسٍم  spesietratpsmnaee semmseepmmiateisrٔ
 -يٍثٕكسً ' 3 -' 0ٔإنى جبَب ْزِ ، كبٌ يب يجًٕعّ انتٕنٍفً الأٔل . يتقبسبت erammnnmببستخذاو  semceeareal
عشض جًٍع انًُتجبث انطبٍعٍت انثلاث الأَشطت انبٍٕنٕجٍت . ، حبٔل أٌضب irrt، يثبظ  atpsmn - spaecarea
أنف ، كًب  aaeeaaelmsnelًْ الأْذاف انًحتًهت انًضبدة نهسشطبٌ انًخذساث ، فً حٍٍ  irrtيثبطبث . قٌٕت
فً انتٕنٍف  paeimcermٔقذ تحقق رنك خطٕة سئٍسٍت يٍ . ٌحًم ٔعذا انًخذساث انًضبدة نًشض انسكش
نحًط كهٕس تهٍٓب تكثٍفّ يع أيٍٍ الاقتضبء ، يع  rermoamcteعٍ طشٌق تحٌٕم حًط  spermpeimrmsne
 aaiemeitmsيٍ سٍطت ، ٔيُبسبت  paeimreeemies aaeeaaelmsnelتى تصٍُعّ يٍ قبم ٔ. ٪ 02انعبئذ الإجًبنً يٍ 
ٔعبشث انًٍضة انشئٍسٍت نتجًٍع ). ٪ 20(، فً حضٕس دي سً سً يع انعبئذ انًشتفع عًٕيب  rermoamcteحبيط 
انتكثٍف يٍ ٔسٍطت انشئٍسٍبٌ يع انعًبنت يٍ يختهف انفئبث  pseemar - atpsmn - spaecarea -يٍثٕكسً ' 3 -' 0
بع َٓج أفضم الاصطُبعٍت انتً تُطٕي عهى انتكثٍف يٍ يشتقبث انكٕيبسٌٍ ٔششٌك ٔاقتشح اتب. ٔاقٍت ٔانقٕاعذ
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THESIS ABSTRACT 
Name:       Shamsuddeen Abdullahi Haladu 
Title:         Total Synthesis of Bioactive Natural Products 
Major:      Chemistry 
Date:         June 2010 
     In the current study the total synthesis of the marine natural products spermatinamine, 
an isoprenylcysteine carboxyl methyltransferase (Icmt) inhibitor, and Aspergillusol A, an 
α-glucosidase inhibitor were accomplished by using a convergent appraoch. Besides 
these, the first total synthesis of 2'-methoxy-3'-prenyl-licodione, an Icmt inhibitor, was 
also attempted. All the three natural products exhibited potent biological activities. The 
Icmt inhibitors are potential anticancer drug targets, while Aspergillusol A, holds promise 
as antidiabetic drug. The key step of amidation in spermatinamine synthesis was achieved 
by transforming the hydroxamic acid to acid chloride followed by condensing it with the 
appropriate amine, with an overall yield of 52%. Aspergillusol A was synthesized by 
estrification of intermediates, erythritol and appropriate hydroxamic acid, in the presence 
of DCC with a high overall yield (60%). Key feature of synthesis of 2'-methoxy-3'-
prenyl-licodione is crossed-claisen condensation of the two key intermediates with 
employment of various protective groups and bases. A better synthetic approach 
involving condensation of coumarin derivative and Grignard partner was proposed.   
Master of Science in Chemistry 
King Fahd University of Petroleum and Minerals 
Dhahran, Saudi Arabia 
June 2010 
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CHAPTER 1 
1.0 INTRODUCTION AND LITERATURE REVIEW 
1.1 Introduction to the natural product syntheses 
      Natural product synthesis is the art and science of constructing the molecules of 
nature in the laboratory and has been a very attractive area for organic researchers across 
the globe today. The enthusiasm to mimic nature and to discover its secrets, by exploring 
efficient ways to synthesize novel and important bioactive natural products, pushes the 
scientists to develop new synthetic methodologies and to explore new chemical 
reactivity.
1
 A flagship of organic synthesis,
1
 natural product synthesis is an efficient tool 
to evaluate the power of existing synthetic methods.  
     The infinite chemical diversity of the natural products provides an enormous challenge 
for synthetic chemists to establish cost-effective means for the construction of these 
unique structures in larger amounts in order to carry out further biological investigations 
and pharmacological studies.
2
 
     Since nature remains the main source of bioactive constituents or leading compounds, 
natural product synthesis will continue to be the leading science with vast opportunities 
for new developments and discoveries.
3
 The advances in drug design and structure-
activity relationship studies have paved a way towards modification of the structure of 
2 
 
 
natural products in order to elevate their potency and augment their selectivity for the 
betterment of their pharmacological properties.
3
 
1.2 Marine Natural Products 
     The Oceans, inhabiting various living organisms have become a great source of 
multitude of active metabolites which can be an ideal resource for the discovery of new 
drugs. 
      Vast and unique organic chemical structures have been observed in the extracts of 
marine organisms. Many of them have been shown to be promising candidates as 
anticancer agent as well as antibiotics.
4
 TZT-1027 is used in cancer chemotherapy, for 
the treatment of leukemia, breast and lung carcinoma and it was developed from marine 
origin natural product
7
 (Dolastatin 10) (Figure 1). 
 
Figure 1: Marine based anti-cancer drugs 
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      Sponges have proved to be the richest source of marine natural products with 
interesting biomedical potentials. Organic compounds synthesized by both sponges and 
microorganisms therein were found to possess potent anticancer, antibiotic, antifungal, 
antiviral, antiparasitic, and antifouling activities.
6 
During the search for novel and new 
anti-cancer drugs, enormous work has been carried out in order to screen the crude 
extracts of marine organisms for biological activity. That research has led to many 
promising findings such as antitumor and/or cytotoxic activities. Further efforts have to 
be focused on translating these bioactivities into useful drugs by using effective pre-
fractionation strategies, advanced identification techniques, and novel synthetic 
methods.
7
 
1.3 Introduction to Icmt Inhibitors 
The protein prenylation, a process initiated by covalent attachment of 15-carbon farnesyl 
or a 20-carbon geranylgeranyl isoprenoids to a conserved cysteine residue, modifies 
many key regulatory proteins in eukaryotic cells at their C-terminus.
8
 This processing 
which is critical for the correct localization and function of these proteins has only been 
studied since 1980s.
9
 However, because of the importance of the biological functions of 
many prenylated proteins, the ensuing 20 years has attracted a lot of interest to study this 
protein modification pathway.
8,10 
For instance, due to critical involvement in many types 
of cancers, members of the Ras GTPase family are extensively studied.
11
 The majority of 
prenylated proteins contain a C-terminal CaaX (C = cysteine residue that is modified, a's 
= aliphatic residues, and X can be any of a number of amino acids such as cysteine, 
4 
 
 
serine, methionine, alanine) motif.
8
 The nature of the X residue dictates whether the 
protein is farnesylated or geranylgeranylated on the cysteine residue of the CaaX 
sequence.
12
 When X is serine, cysteine, alanine or glutamine, the 15-carbon farnesyl 
group is added to the cysteine residue by protein farnesyltransferase (FTase), whereas if 
the X is leucine, then the 20-carbon geranylgeranyl group is added by protein 
geranylgeranyltransferase type I (GGTase-I), followed by proteolytic removal of the aaX 
residues by the endoprotease Rcel.
13,14
 The resultant exposed carboxyl group on 
prenylated cysteine is then methylated by isoprenylcysteine carboxylmethyltransferase 
(Icmt).
15,16
   
     The three-step modification of CaaX proteins is generally important for membrane 
association and protein localization in the cell as well as in protein-protein 
interactions,
17,18
 which are indispensable for many specific functions of these proteins. 
Recent studies have shown that even though methylation as the third step is less 
important for hydrophobicity of the CaaX proteins, especially those that are modified by 
the 20-carbon geranylgeranyl isoprenoid,
18,19
 the modification is nevertheless important 
to the function of these proteins.
21,23
 
Prenylation of the CaaX proteins has attracted considerable interest, in large part 
because of the key role of the activated form of Ras in the pathogenesis in the human 
cancers 
11
 and that the growth of Ras dependent tumors in mice can be inhibited by 
pharmacological blockade of FTase by FTIs (farnesyltransferase inhibitors).
24-26
 In 
addition, Ras GTPases and other CaaX proteins are involved in an array of signaling 
pathways that are important in other pathologies dependent on aberrant proliferation, 
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such as inflammation
11,27
. However, FTIs have not performed up to expectation in solid 
tumors and failed to respond in many types of cancer, even those with activated RAS 
oncogenes
28-31
. The multifactorial nature of human cancer and “alternative prenylation”, a 
process whereby CaaX proteins including some Ras isoforms can be modified by 
GGTase-I when FTase is inhibited, cause this variability
32-33
. The disclosure of 
alternative prenylation sparked interest in finding inhibitors of GGTase-I and activated 
forms of both farnesylated and geranylgeranylated CaaX proteins by inhibition of the 
distal processing steps in the pathway, i.e., Rce1 or Icmt, since there is a single enzyme 
for both of these steps that processes both farnesylated and geranylgeranylated 
proteins.
34-35
 Thus, the blockade of one of these steps would be expected to impact all 
Ras isoforms. Indeed, recent studies have shown that genetic disruption of Icmt in cells 
dramatically attenuates their ability to be transformed by oncogenic K-Ras
23
 and 
treatment of a human colon cancer cell line with a specific Icmt inhibitor blocks 
anchorage-independent growth of the cancer cells 
22
.         
     Considering the fact that Icmt-catalyzed CaaX protein methylation plays a crucial role 
in oncogenesis, the quest for specific inhibitors of this process has increased in recent 
years. One of the approaches adopted in the pursuit of anti-cancer drugs is the 
development of Icmt inhibitors
36
 and there are ongoing efforts to assess the potential of 
targeting Icmt in anticancer drug discovery. The discovery of new Icmt inhibitors 
concluded bioassay-directed purification of extracts of Hovea parvicalyx I. Thomps 
(Fabaceae) affording two new prenylated β-hydroxychalcone derivatives (1) and (2)37, 
which showed inhibition of Icmt with an IC50 of 30 and 17 M, respectively (assay 
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performed in duplicate on two independent days). In addition, the Australian marine 
sponge, Pseudoceratina sp., yielded spermatinamine (3)
38
, a novel alkaloid with a 
bromotyrosyl-spermine-bromotyrosyl sequence, showing inhibition of Icmt at an IC50 of 
1.9 M (assay performed in duplicate on five independent days). Spermatinamine (3) is 
the first natural product inhibitor of Icmt. Compounds (1-3) (Figure 2) are considered a 
new addition to the small list of inhibitors of Icmt.
37,38
 
1.4 Literature Review of Icmt Inhibitors 
     Interest in targeting Icmt in cancer therapy goes back to as early as 1991 when 
farnesylcysteine analogue N-acetyl-S-farnesyl-L-cysteine (AFC; 5, Fig. 2) was studied as 
an inhibitor of carboxyl methylation of CaaX proteins
40
. In this study, although AFC was 
reported to inhibit methylation of Ras in transformed fibroblast cells but it had little effect 
on the rates of proliferation of these cells. Another prenylcysteine analogue 
farnesylthiosalisylic acid (FTS; 6, Figure. 2) was found to inhibit the methylation of 
GTP-binding proteins such as Ras
41
 in a cell-free system and  FTS treatment interferes 
with the growth of human H-Ras-transformed Rat1 cells, but has only minimal 
cytotoxicity in a variety of other transformed cell lines.
42
 These studies have disclosed 
that all prenylated proteins are not equally affected by the treatment of cells with the 
inhibitor especially Ras proteins, which were seen to be more affected by FTS treatment 
than some other CaaX proteins. This finding revealed that the cellular activity of FTS 
was more likely due to its ability to dislodge Ras from membranes rather than its ability 
to inhibit CaaX protein methylation.
42,43 
A number of studies show doubt on whether the 
observed biological effects of treating cells with prenylcysteine analogues were actually 
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due to Icmt inhibition. For instance, inhibition of macrophage chemotaxis by AFC was 
later linked to the direct blockade of the interaction between receptor and G-proteins (the 
latter of which, of course, contain a CaaX protein subunit) rather than inhibition of 
carboxyl methylation.
44
 Additional studies have concluded that compounds such as AFC 
have significant effects on cells via an impact on processes that do not involve inhibition 
of Icmt.
45,46
    
      Mechanistically distinct approaches, to bring about increased levels of AdoHcy(S-
adenosylhomocysteine(AdoHcy)) in cells, to target Icmt have been employed. Using a 
variety of methods, the inhibition of Icmt was demonstrated to be resulted from 
proliferation in a number of cell types,
47
 and an increase in apoptosis in endothelial cells 
in particular.
48,49
 The classic anticancer therapeutic methotrexate was also employed to 
elevate AdoHcy in cancer cells, which profoundly inhibited Ras methylation coupled 
with mislocalization and a significant decrease in Ras signaling
50
. Although AdoHcy is 
not a selective inhibitor of Icmt, but rather a general inhibitor of cellular 
methyltransferases.
51
 These studies nonetheless supported the hypothesis that targeting 
Icmt might inhibit the proliferation of cancer cells and enhance their apoptotic death.   
     In an attempt to move beyond substrate- and product-based inhibitors of Icmt and 
discover a pharmacological agent with higher potency and selectivity, the screening of a 
diverse chemical library has led to the identification of a selective small-molecule 
inhibitor of Icmt, cysmethynil (7, Figure. 2).
22
 Treatment of human colon cancer cells 
with cysmethynil generated many of the same cellular characteristics noted above with 
the Icmt knockout models, including Ras mislocalization, impaired Ras signaling and 
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inhibition of oncogenesis as assessed by tumor cell growth in soft agar. Moreover, these 
effects were reversible upon overexpression of Icmt, indicating mechanism based activity 
of the compound. Also, cysmethynil treatment did not impair the proper localization of 
membrane protein modified by myristol/palmitoyl, demonstrating that the compound 
does not cause a global disruption of protein trafficking to the cell membrane. The 
identification of cysmethynil as an Icmt inhibitor has provided a selective 
pharmacological tool to probe the potential functional consequences of CaaX protein 
methylation in cellular systems and also the involvement of Icmt in both normal and 
pathological cellular processes.  
     The search for new Icmt inhibitor was extended to natural sources and purification of 
extracts of Hovea parvicalyx I. Thomps (Fabaceae) afforded two new prenylated β-
hydroxychalcone derivatives (1) and (2)
37
, whereas Buchanan et al., has reported the 
isolation of spermatinamine (3) (see Figure 2) from the Australian marine sponge 
Pseudoceratina sp, the first natural product inhibitor of Icmt.
38
 The same research group 
has reported the isolation of aplysamine 6 (4)
36
, an inhibitor of Icmt with an IC50 of 14 
M.  
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Figure 2: Examples of Icmt Inhibitors 
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1.5 Introduction and Literature Review of α-Glucosidase Inhibitors 
1.5.1 α- Glucosidase 
α–Glucosidase and α–Amylase are enzymes that catalyze the metabolism of 
carbohydrates. Glycoside trimming enzymes are important in a broad range of metabolic 
pathways, for processing of glycoproteins and glycolipids, and for the digestion of 
carbohydrates in the gut. α-amylases present in the saliva and pancreas are responsible 
for the breakdown of complex polysaccharides into oligo- and disaccharides, and 
preparing them for absorption. α -Glucosidase is a collective name for the enzymes 
maltase, sucrase, isomaltase and glucoamylase, and is a membrane bound enzyme present 
in the brush border of the small intestine. It is present in relatively high concentrations in 
the proximal part of the jejunum and gradually decreases in the distal region, with 
practically zero levels at the ileum. This enzyme catalyzes the final step in the digestive 
process of carbohydrates, which is the conversion of the disaccharides sucrose and 
maltose into glucose.  
1.5.2 α-Glucosidase Inhibitors 
     α-Glucosidase inhibitors (acarbose 8, miglitol 10, voglibose 9) (Figure 3) are drugs 
that delay the breakdown of carbohydrates in the gut, and consequently slow down the 
absorption of sugars into the blood stream. Such processes control postprandial glucose 
levels and suppress postprandial hyperglycemia. These inhibitors are grouped as 
antihyperglycemic drugs and patients with type 2 diabetes may use them 
therapeutically.
53
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    In was discovered in the 1970s that inhibition of all or some of the intestinal 
disaccharidases and pancreatic α-amylase by inhibitors could regulate the absorption of 
carbohydrate and these inhibitors could be used therapeutically in the oral treatment of 
the non-insulin-dependent diabetes mellitus (type II diabetes).
54
 Valiolamine (12, Figure 
3), produced by  Streptomyces hygroscopicus var. limoneus was found to inhibit pig 
intestinal maltase and sucrase with IC50 values of 2.2 and 0.049 mM, respectively.
54
 
Several N-substituted valiolamine derivatives were synthesized to enhance its α-
glucosidase inhibitory activity in vitro and one simple derivative Voglibose (9, Figure 3), 
which was obtained by reductive amination of valiolamine with dihydroxyacetone, was 
selected as the potential oral antidiabetic agent and has been commercially available for 
the treatment of diabetes in Japan since 1994. Nojirimycin (15, Figure 3), a potent 
inhibitor of α- and β-glucosidases, isolated from Bacillus species was discovered as the 
first glucose analog with the nitrogen atom in place of the ring oxygen. Another potent α-
glucosidase inhibitor Genistein 16 a soy isoflavone isolated from the fermentation broths 
of Streptomyces species has been demonstrated to be a reversible, non-competitive 
enzyme inhibitor.
55
  
     The presence of polyhydroxy groups on Nojirimycin and  Genistein  is critical for α-
glucosidase inhibition activity, since most mimic the natural substrates maltose and 
sucrose. However, because this Nojirimycin (iminosugar) with the hydroxyl group at C-1 
is fairly unstable, it is usually stored as bisulfite adducts or it may be reduced by catalytic 
hydrogenation with a platinum catalyst or by NaBH4 to 1-deoxynojirimycin (DNJ) (11, 
Figure 3). DNJ was later isolated from the roots of mulberry trees and called molanoline. 
Similarly, Salacinol (13, Figure 3) and kotalanol (14, Figure 3) have been identified as α-
12 
 
 
glucosidase-inhibiting components from the water-soluble fraction of the roots and stems 
of S. reticulate.
53
  
     Among the carboxylic acid derivatives, of particular interest are two bioactive 
compounds isolated from the rhizomes of Kaempferia galanga, 4-methyl-transcinnamic 
acid (17, Figure 3), which is a non competitive inhibitor of the enzyme, and its 
corresponding ethyl ester 18, which competitively inhibits maltase. The methoxy 
derivative of cinnamic acid showed improved enzyme inhibitory activity, but replacing 
the electron rich hydroxy groups on the molecule, or introduction of an electron 
withdrawing nitro group renders the compound inactive. 
56
 
       Recently, in outgoing efforts to discover new bioactive chemical entities from marine 
sources, chemical exploration of the fungus Aspergillus aculeatus has led to the isolation 
and structure elucidation of aspergillusol A 19, a tyrosine-derived metabolite featuring 
hydroxyphenylpyruvic acid oxime moieties linked to erythritol through ester linkage.
58
 
The aspergillusol A 19 selectively inhibited α-glucosidase from the yeast Saccharomyces 
cerevisiae with the IC50 value of 456  2 (M). 
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Figure 3: α-Glucosidase Inhibitors 
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CHAPTER 2 
2.0 OBJECTIVES AND WORK PLAN 
The following are the objectives of this research studies 
1) To achieve the total synthesis of four different natural products, sprermatinamine 3 and 
a prenylated β-hydroxychalocone derivative 1. These compounds are potential anticancer 
agents, while Aspergillusol A 19, isolated from the fungus Aspergillus aculeatus, exhibits 
anti-diabetic activity.  
2) Objective 1 would help to establish a facile and cost-effective synthetic methods to 
access these compounds in large quantities. This in turn would serve to carry out further 
screening and pharmacological studies and help in discovering more potent anti-cancer 
and anti-diabetic drugs. 
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Figure 4: Target Molecules 
 
2.1 Methodology and the Work Plan 
2.1.1 Synthesis of Spermatinamine 
In order to accomplish the synthesis of target molecule 3, intermediate 24 would 
be required, which would be synthesized as outlined in Scheme 1. Bromination of the 
aldehyde 20
38,40 
followed by methylation would generate aldehyde 22. Exposure of the 
latter to acetylglycine and acetic anhydride at higher temperature would furnish 
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intermediate 23, which would be then treated with 4-methoxybenzyloxylamine 
hydrochloride
59
 or benzyloxylamine hydrochloride to produce the target intermediate 24 
(Scheme 1). 
 
Scheme 1: Work plan of the synthesis of Intermediate 24 
 
The other intermediate 31 needed to execute the synthesis of the target molecule 3 will be 
synthesized as follows. Protection of butane-1,4-diamine 25 with (Boc)2O followed by 
alkylation of the resulting dicarbamate 26 with methyliodide in presence of sodium 
hydride as a base will furnish compound 27. Deprotection of 27 in a mixture of methanol 
and acetyl chloride will yield N,N’-dimethylbutane-1,4-diamine hydrochloride 28 which 
will be treated with aqueous NaOH to librate the free amine 29. Compound 29 will be 
subjected to Michael addition with acrylonitrile to yield the intermediate 30, which will 
be subjected to hydrogenation using palladium on activated charcoal to produce 
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tetraamine 31. Amidation of the  latter amine 31 with 24, followed by the deprotection of 
the resulting oxime would produce spermatinamine 3 (Scheme 2). 
 
 
Scheme 2: Work plan of the synthesis of spermatinamine 
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2.2 Synthesis of Aspergillusol A (19) 
     To achive the synthesis of Aspergillusol A 19, the key intermediate erythritol 35 
according to
(67)
 would be synthesized as follows: Selective protection of L-arabinose to 
form the acetonide 33, followed by oxidative cleavage with sodium periodate to produce 
the intermediate 34. Reduction of the latter with sodiumborohydride will furnish 35 
(Scheme 3). 
 
 
Scheme 3: Work plan of the synthesis of erythritol derivative 
 
     The synthesis of pyruvic acid oxime 39, required to furnish the synthesis of 
aspergillusol 19 will start from the reaction of aldehyde 36 with hippuric acid and sodium 
acetate at higher temperature to get intermediate 37, which will be subjected to basic 
hydrolysis to produce pyruvic acid 38. Condensation of the latter acid 38 with 
benzyloxylamine hydrochloride would then produce 39. 
      Condensation of the pyruvic acid oxime 39 with erythritol 35 in presence of DCC and 
DMAP will produce Aspergillusol A 19 (Scheme 4). 
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Scheme 4: Work plan of the syntthesis of Aspergillusol A 
 
2.3 Synthesis of β-Hydroxychalcone Derivative 
In the course of synthesis of target molecules 1, we would need a key 
intermediate 49, which in turn would be synthesized as outlined in Scheme 5. Acetylation 
of 1,3-dihydroxybenzene 42 in acetic acid would furnish 43,
52 
which would be subjected 
to alkylation with allyl bromide 44 to obtain compound 45. The claisen rearrangement of 
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the latter would generate intermediate 46, which would be subjected to olefin metathesis 
using second generation-Grubbs catalyst would render compound 47. The regioselective 
protection of 47 with DHP would generate phenol 48, which would be alkylated with 
methyl iodide to give the desired intermediate 49. 
 
Scheme 5: Work plan of the synthesis of 49 
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     Synthesis of the target molecule 1 would be accomplished as outlined in Scheme 6. 
Protection of 50 would yield intermediate 51. Condensation of 49 and 51, using a suitable 
base at low temperature will construct 1,3-dione 52,
60 
which will be finally deprotected to 
produce the desired target compound 1.  
 
 
Scheme 6: Work Plan of the synthesis of 1 
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CHAPTER 3 
3.0 RESULTS AND DISCUSSIONS 
3.1 Synthesis of Spermatinamine (3) 
     Retrosynthetically, the synthesis of spermatinamine 3 was envisioned from two key 
intermediates namely: the dibromotyrosine derivative 24 and spermine derivative 31, 
which in turn could be realized from aldehyde 20  and the diamine 25, respectively 
(Scheme 7).   
24 
 
 
 
Scheme 7: Retrosynthesis of Spermatinamine 
 
     The synthesis of intermediate 24 was commenced from the bromination of aldehyde 
20 to get the dibromoaldehyde 21 in 95% yield, which was subjected to alkylation with 
iodomethane in DMF, using K2CO3 as a base to obtain methyl ether 22 in quantitative 
yield (Scheme 8). Aldehyde 22 was condensed with N-acetyl glycine 53 in acetic 
anhydride to yield the intermediate 23 in 78% yield. The hydrolysis of compound 23 in 
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basic condition yielded the α-ketoacid 54, which was condensed in situ with 
benzyloxylamine to obtain the desired dibromotyrosine derivative 24 (34% for two steps)  
 
Scheme 8: Synthesis of intermediate 24 
 
     The synthesis of the intermediate 31 was started from N-protection of butane-1,4-
diamine (25)  with (Boc)2O in dichloromethane at room temperature to get compound 26, 
which was subjected to alkylation with iodomethane in THF to furnish the intermediate 
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27 in high yield (80% for two steps) (Scheme 9). The deprotection of compound 27 was 
carried out in methanol at 0
o
C, followed by the dropwise addition of acetyl chloride, 
stirring the reaction mixture overnight at room temperature to obtain the desired N,N’-
dimethylbutane-1,4-diamine hydrochloride 28 in quantitative yield. Compound 28 was 
transformed to its free amine form 29 by treating it with aqueous NaOH, followed by 
extraction with dichloromethane. Michael addition of compound 29 with acrylonitrile in 
ethanol, stirring the overnight at room temperature to get the intermediate 30 in 93% 
yield. The desired spermine derivative 31 was finally obtained from compound 30 by 
subjecting it to hydrogenation in a pressure vessel in parr apparatus in a mixture of 
ethanol and aqueous sodium hydroxide at 50 psi for 6 h, using Ra-Ni as the catalyst. 
Initial attempt to hydrogenate 30 using Palladium on activated charcoal gave a complex 
mixture of products, difficult to identify by NMR.  
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Scheme 9: Synthesis of Dimethylspermine 
 
      An attempt to access intermediate 29 through reaction of methylamine hydrochloride 
and 1,4-dibromobutane was not successful, ending up with mixture of products.  
     In another attempt to access 29, 1,4-dibromobutane was reacted with N-
methylbenzylamine in the presence of potassium carbonate and catalytic amount of 
sodium iodide in acetonitrile
69
 but the reaction did not yield the desired product (Scheme 
10). 
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Scheme 10: Synthesis of intermediate 29 
        
       To prepare the advanced intermediate 56, coupling of the two key intermediates, the 
protected oxime acid 24 and the dimethyl spermine 31 was achieved through the 
activation of 24 to the corresponding acid chloride 55, followed by adding it at 0 
o
C to a 
solution of 31 in a mixture of THF and DMF, using 2,6- lutidine as a base and stirring the 
reaction mixture at room temperature for 2 h (Scheme 11). Hydrogenation of 56 in parr 
vessel at 30 psi, using palladium on activated charcoal afforded the target 
spermatinamine 3 in 52% yield. Initial use of coupling agents (DDC, HOBt and 2,6 
lutidine) to generate 56 proved unsuccessful. 
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Scheme 11: Final steps of the synthesis of spermatinamine 
 
3.2 Synthesis of Aspergillusol A (19) 
      The synthesis was started with the preparation of protected erythritol derivative 35, as 
outlined in Scheme 12. Based on wang’s procedures,66 L-arabinose was selectively 
protected as its acetonide 33 by reacting it with 2,2-dimethoxypropane in DMF which 
was reacted, without purification, with sodium periodate to afford 2,3-O-isopropylidene-
L-erythrose 34. 
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Scheme 12: Synthesis of erythritol derivative 
 
     The subsequent reduction of 34 with sodium borohydride in methanol to erythritol 
derivative 35
65
 was not satisfactory in our hands, yielding only 10% of the desired 35. 
However, the yield of compound 35 was improved to 60% by optimizing the reaction 
conditions by carrying it out in ethanol and neutralizing it with acetic acid after reaction 
completion (Scheme 12). 
      To acquire hydroxyphenylpyruvic acid oxime 39, needed to be condensed with the 
erythritol derivative 35, we were required to synthesize phenylpyruvic acid derivative 38. 
The synthesis of 38 was achieved by reacting aldehyde 36 with hippuric acid to afford 37, 
followed by the basic hydrolysis of 37
69
 to produce compound 38 (Scheme 13).
 
The 
condensation of 38 with hydroxybenzylamine hydrochloride in dioxane at 40 
o
C, using 
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sodiumbicarbonate as a base produced the desired phenylpyruvic acid oxime derivative 
39 in 48% yield.  
 
 
Scheme 13: Synthesis of intermediate 39 
 
      The estrification of oxime 39 with erythritol derivative 35 was attempted in CH2Cl2 
by reacting it with DCC and a catalytic amount of 4-(dimethyamino)pyridine at 0 
o
C for 
1.5 h to afford the desired ester 40 in 70% yield (Scheme 14). In an initial trial, the 
temperature of the reaction was raised to room temperature after the addition of DCC and 
4-(dimethyamino) pyridine at 0 
o
C and the reaction was completed in 20 minutes but 
resulted with many side products and 25% yield of 40.  
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Scheme 14: Final steps of the synthesis of Aspergillusol A 
 
        The deprotection of the acetonide of 40 was first attempted with dilute HCl in THF 
at room temperature but the reaction gave 15% of the desired diol 41. Thus the 
deprotection was carried out with TFA in a mixture of H2O and THF, and stirred for 72 h 
at room temperature to afford 41 in 88% yield. The deprotection of the benzyl groups 
were ensued by hydrogenation using a catalytic amount of Pd/C under the pressure of 50 
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psi in a mixture of THF and ethanol for 3 h to yield 19 in 58% yield (Scheme 14).  The 
spectral data of 19 matched the reported values of the previously isolated material.
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3.3 Synthesis of 2’-methoxy-3’-prenyl-licodione (1) 
 
 
Scheme 15: Retrosynthesis of 1 
 
        From retrosynthesis standpoint the synthesis of 1 was envisioned from two key 
intermediates, the highly functionalized hydroxyketone 58 and the phenolic ester 50, 
which were to be subjected to claisen condensation (Scheme 15). 
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3.3.1 Synthesis of the intermediate 58 
      The synthesis of 58 began from acetylation of resorcinol 42 refluxing with acetic acid 
in the presence of zinc chloride to yield the mono-acetylated resorcinol 43 in good yield 
(76%). The latter was subjected to alkylation with allylbromide in presence of potassium 
carbonate as a base to afford compound 45 in 90 % yield after separating the diallylated 
side-product by acid-base treatment (Scheme 16). 
   
 
Scheme 16: Synthesis of Intermediate 60 
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      Claisen rearrangement of intermediate 45 was executed in N,N-dimethylaniline at 
very high temperature to afford intermediate 46 in 60% yield. Regioselective protection 
with benzoyl chloride afforded 59, which was subjected to methylation with 
iodomethane, using potassium carbonate as a base to produce 60.  
 
3.3.2 Synthesis of methyl 4-hydroxybenzoate (50) 
        Esterification of 61 in methanol and sulfuric acid afforded the intermediate 50 in 
98% yield. The latter was treated with benzoyl chloride to generate intermediate 62. 
 
 
Scheme 17: Synthesis of intermediate 62 
 
     Having the desired intermediates (60 and 62) in hand, cross claisen condensation 
reaction of the two in presence of LDA as a base proved to be unsuccessful. Instead, 
benzoyl deprotection was only observed. We tried alternative basis such as LiHMDS and 
NaH, but no coupling product was observed in any case, the benzoyl group deprotection 
was witnessed instead (Scheme 18). 
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Scheme 18: Synthesis of Intermediate 63 
 
       With the aim to force the coupling conditions, the more robust p-methoxybenzyl 
(PMB) protection was chosen but yet the desired coupled product was not observed, and 
only the hydrolysis of the ester took place (Scheme 19). 
 
Scheme 19: Synthesis of Intermediate 67 
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     Cross – claisen reaction with potassium hydroxide in pyridine was also tried but it was 
not successful either. 
 
Scheme 20: KOH mediated Synthesis of Intermediate 67 
 
       Owing to the failure in cross-claisen reaction, we opted another approach toward the 
synthesis of 1. 
      The new approach involved the synthesis of the hydroxy-coumarin A derivative and 
grignard reagent B to access the coupled intermediate C, which will further undergo 
modifications to construct the final target 1. 
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Scheme 21:  Alternate approach to synthesize 1 
 
      To prepare the lactone 72 the hydroxyketone 68 was condensed with diethyl 
carbonate 69 using sodium hydride as a base under reflux
67 
but no cyclization was 
observed. The starting compound 68 was recovered instead (Scheme 22). 
 
Scheme 22: Synthesis of intermediate 72 with diethyl carbonate 
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      Cyclization with  2,2,2-trichloroethyl carbonochloridate 71 also met with failure. So 
was the case with benzylchloroformate (Scheme 23).   
 
Scheme 23: Synthesis of 72 with trichloroethyl carbonochloridate and 
benzochloroformate 
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     The cyclization of compound 45, however, was successful by refluxing it with diethyl 
carbonate in dry benzene, using sodium hydride as a base (Scheme 24). 
 
Scheme 24: Synthesis of intermediate 73 
 
     The next step was the protection of the hydroxyl group of coumarin derivative 73, 
prior to claisen rearrangement. This was first attempted with TBSCl but the desired 
product was not obtained. 
 
Scheme 25: TBS protection of 73 
 
      The protection was also tried using PMBCl in DMF heating the mixture at 100 
o
C and 
then stirring at room temperature, using sodium hydride as a base,
68
 which rendered a 
very low yield of the desired product 75 along with undesired C-dialkylated product 76 as 
the major product (Scheme 25). 
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Scheme 26: PMB protection of 73 
     Protection with dimethyl sulfate and potassium carbonate in acetone was, however, 
successful rendering a high yield (80%) of the desired 77. Claisen rearrangement of 77 
was carried out in decalin
68
 to yield 78 in 60% yield. 
 
Scheme 27: Synthesis of intermediate 78 
 
     The next steps toward the total synthesis of our target molecule will require protection 
of the hydroxyl group using PMBCl or TBSCl followed by coupling of 78 with grignard 
reagent, methylation, olefin metathesis and finally deprotection to afford 1. 
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Scheme 28: Proposed route for the synthesis of 1 
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CHAPTER 4 
4.0 EXPERIMENTAL WORK 
4.1 Instrumentation and Chemicals 
1
H NMR and 
13
C NMR spectra were recorded on JEOL Lambda 500 and 400 MHz 
spectrometer. Chemical shifts were reported in ppm (δ) relative to tetramethyl silane 
(TMS) by using (CDCl3), (DMSO) or methanol as deuterated solvents. Multiplicities 
were reported as singlet (s), doublet (d), triplet (t), quartet (q) or multiplet (m), and 
coupling constants (J) were reported in hertz (Hz). IR Spectra were recorded on a 
NicoletTM 6700 FT-IR spectrometer from a thermo-electron by using a smart orbit for 
net samples, and they were reported in wave numbers (cm
-1
) (Spectral resolution, 4 cm
-1
; 
Number of scans, 4). Mass was determined by using Agilent 7000A Triple Quadrupole 
GC/MS.  
     Elemental analysis was carried out on a EuroVector Elemental Analyzer Model 
EA3000. All mps are uncorrected. Thin layer chromatography (TLC) was frequently used 
to monitor reactions and to give qualitative determination of sample purity. TLC analyses 
were performed on silica gel Merck 60 F254 plates, and spots were visualized under a 
spectroline UV lamp operating at short and long wavelength ranges. Visualization was 
improved by dipping plates into a phosphomolybdic acid solution, and then by drying in 
a blast of hot air. Purification of the products was carried out either by recrystallization or 
by flash column chromatography. The column was packed with silica gel 100 from Fluka 
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Chemie AG (Buchs, Switzerland). Ethyl acetate, petroleum ether (boiling fraction 60-80) 
and hexane were used as eluting solvents, in volume-by-volume ratios as stated.       
     Chemicals were purchased from commercial sources, and they were used without any 
further purification unless otherwise specified. All solvents were of reagent grade, and 
dichloromethane was passed through alumina before use. Specially dried 53 (anhydrous) 
solvents were used where necessary. Glassware for moisture-sensitive reactions were 
oven dried at 120-140 °C for at least three hours and cooled in a desiccators prior to use. 
Some of the reactions were run in an inert atmosphere of nitrogen as stated. 
4.2 Synthesis of Spermatinamine 
4.2.1 Synthesis of 3,5-Dibromo-4-hydroxybenzaldehyde (12) 
 
     Bromine (30.2 g, 190 mmol) in AcOH (50 mL) was added to a mixture of 4-
hydroxybenzaldehyde (11 g, 90 mmol) and sodium acetate (22.9 g, 279 mmol) in AcOH 
(200 mL) at room temperature over 20 min. The reaction mixture was stirred for 1 h at 
room temperature. A solid precipitated after H2O (200 mL) was added. After filtration, 
the solid was washed with H2O and dried in a vacuum desiccators with P2O5 overnight to 
afford 12 as a pale-yellow solid (24.1 g, 96%). 
1
H NMR (300 MHz, CDCl3): δ 6.43 (s, 
1H), 8.00 (s, 2H), 9.80 (s, 1H); 
13
C NMR (75 MHz, acetone-d6): δ 112.4, 132.7, 157.0, 
135.0, 189.8. 
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4.2.2 Synthesis of 3,5-dibromo-4-methoxybenzaldehyde (13)  
 
     To a mixture of aldehyde 12 (3 g, 10.71 mmol) in DMF (30 mL) was added potassium 
carbonate (2.22 g, 16.1 mmol), followed by the addition of methyl iodide (1.98 g, 13.9 
mmol) at room temperature and the mixture was stirred overnight at room temperature. 
The reaction mixture was diluted with ethyl acetate (40 mL) and washed successively 
with water (20 mL), 2M HCl (20 mL x 2), brine (15 mL), dried over anhydrous sodium 
sulfate and evaporated under reduced pressure to afford 13 as a yellow solid (3.05g, 
97%). 
1
H NMR (500 MHz, CDCl3): δ 3.97 (s, 3H), 8.03 (s, 2H), 9.86 (s, 1H); 
13
C-NMR 
(125 MHz, CDCl3): δ  119.31, 133.91, 134.20, 159.12, 188.43. 
4.2.3 Synthesis of (Z)-4-(3,5-dibromo-4-methoxybenzylidene)-2-methyloxazol-
5(4H)-one (15) 
 
     A mixture of aldehyde 13 (3.02 g, 8.05 mmol), sodium acetate (8.00 mg, 9.6 mmol), 
and N-acetylglycine (943 mg, 8.05 mmol) in Ac2O (12.5 mL) was stirred at 120 °C for 4 
h. A yellow solid was crushed out upon cooling the reaction mixture to room 
temperature. After filtration, the solid was washed with cold 1:1 pentane/Et2O to yield 15 
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as a yellow solid (2.92 g, 97%); mp: 154-155 
oC; IR (Neat) νmax 3233, 2927, 1692, 1662, 
1633, 1468, 1416, 1365, 1255, 1201, 981, 902, 721 cm
-1
. 
1
H NMR (500 MHz, DMSO-
d6): δ 2.40 ( s, 3H), 3.83 (s, 3H), 7.16 (s, 1H), 8.47 (s, 2H). 
13
C NMR (125 MHz, DMSO-
d6): δ 15.52, 60.73, 117.89, 125.70, 132.28, 133.88, 135.65 , 154.94, 166.88, 168.04. 
4.2.4 Synthesis of (Z)-2-(benzyloxyimino)-3-(3,5-dibromo-4-
methoxyphenyl)propanoic acid (16) 
 
     A suspension of azlactone 15 (2.2 g, 4 mmol) and Ba(OH)2 (4.8 g, 28 mmol) in a 
mixture of dioxane:H2O (1:1, 56 mL) was stirred at 60 °C for 1 h, followed by the 
addition of O-Benzylhydroxylamine hydrochloride (2.05 g, 12.8 mmol) and the mixture 
was stirred vigorously at the same temperature for 6 h. The reaction mixture was cooled 
to 0°C and acidified to pH 4 with 10% HCl and extracted with EtOAc (50 mL x 2). The 
combined organic extracts were washed with H2O, dried over MgSO4, and evaporated 
under reduced pressure. The yellow oily material was loaded on silica column eluting 
with EtOAc:MeOH (10:1)  to afford 16 (1.37g, 75%) as a pale-yellow solid; mp: 115 
o
C; 
IR (Neat) νmax 3060, 2943, 1692, 1589, 1471, 1416, 1259, 1219, 991.1, 897, 738, 696 cm
-
1
. 
1
H NMR (500 MHz, CDCl3): δ 3.80 (s, 2H), 3.83 (s, 3H), 5.30 (s, 2H), 7.40-7.26 (m, 
7H). 
13
C NMR (125 MHz, CDCl3): δ 29.13, 78.74, 117.99 (2C), 128.56 (2CH), 128.84 
(3CH), 133.38 (2CH), 133.59, 135.36, 148.89, 153.03, 163.31. 
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4.2.5 Synthesis of tert-butyl butane-1,4-diyldicarbamate (18) 
 
     To a solution of butane-1,4-diamine 17 (7 g, 79.4 mmol) in dichloromethane (100 mL) 
was added di-tert-butyl dicarbonate (38.1 g, 174.7 mmol) and the reaction mixture was 
stirred for 4 hours at room temperature. The solvent was evaporated under reduced 
pressure to yield white precipitates which were collected by filtration and washed with 
ether to yield 18 as a white solid (21.75 g, 95%). IR (Neat) νmax 3335, 2975, 2936, 2868, 
1686, 1528, 1315, 1362, 1276, 1167, 1014, 905, 661 cm
-1
. 
1
H NMR (500 MHz, CDCl3) 
(data for monomer): δ 1.44 (s, 9H), 1.5 (s, 2H obscured by the preceding peak), 3.12 (s, 
2H), 4.57 (br s, 1H). 
13
C NMR (125 MHz, CDCl3) (data for monomer): δ 27.39, 28.39 
(3CH3), 40.19, 79.13, 155.96.  
4.2.6 Synthesis of tert-butyl butane-1,4-diylbis(methylcarbamate) (19) 
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     To a solution of 18 (20.28 g, 54.87 mmol) in THF (200 mL) at 0
o
C was added sodium 
hydride (2.77 g, 115.2mmol), followed by dropwise addition of iodomethane (19.47 g, 
137.2mmol). After being stirred overnight at room temperature, the reaction mixture was 
diluted with ethyl acetate (100 mL) and successively washed with water (30 mL), brine 
(30 mL), dried over sodium sulfate and concentrated under vacuum. The crude mixture 
was column chromatographed using ethyl acetate (100%) as an eluent to yield the title 
compound 19  as a yellow liquid (14.49 g, 85%). IR (Neat) νmax 2972, 2928, 1687, 1455, 
1393, 1364, 1311, 1217, 1153, 877, 732 cm
-1
. 
1
H NMR (500 MHz, CDCl3), (data for 
monomer): δ 1.45 (s, 9H), (s, 2H, obscured by the preceding peak), 2.82 (s, 3H), 3.21 (s, 
2H). 
13
C NMR (125 MHz, CDCl3), (data for monomer): δ 24.93, 28.41 (3CH3), 48.50, 
155.75. 
4.2.7 Synthesis of N,N’-dimethylbutane-1,4-diamine hydrochloride (29) 
 
     To a solution of compound 19 (14 g, 74 mmol) in methanol (100 mL) at 0 
o
C was 
added acetyl chloride (6.3 mL, 89 mmol) dropwise and the reaction was stirred overnight 
at room temperature. The solvent was evaporated under vacuum to yield the 
corresponding ammonium salt (13.8 g, quantitative yield) as a white solid, which was 
converted to its free amine form by dissolving it in 10% aqueous NaOH and extracting it 
with dichloromethane (60 mL x 3). The organic layer was dried over anhydrous Na2SO4 
and evaporated in vacuo to yield compound 29 as a pale yellow oil. 
1
H NMR (500 MHz, 
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CDCl3), (data for monomer): δ 1.52 (s, 2H), 1.65 (s, 2H), 2.42 (s, 3H), 2.58 (2H).  
13
C 
NMR (125 MHz, CDCl3), (data for monomer): δ 27.54, 36.34, 51.87. 
4.2.8 Synthesis of 3,3'-(butane-1,4-diylbis(methylazanediyl))dipropanenitrile (21) 
 
     To a solution of N,N'-dimethylbutane-1,4-diamine 29 (10 g, 86 mmol) in ethanol at 
0
o
C was added  acrylonitrile (960 mg, 180.7 mmol) and the mixture was stirred overnight 
at room temperature. The solvent was evaporated under reduced pressure to yield 21 as a 
yellow liquid  (17.78 g, 93%). IR (Neat) νmax 2940, 2851, 2798, 2246, 1728, 1460, 1368, 
1255, 1136, 1048 cm
-1
. 
1
H NMR (500 MHz, CDCl3), (data for monomer): δ 1.50 (m, 2H), 
2.27 (s, 3H), 2.42 (s, 2H), 2.48 (t, 2H), 2.71 (m, 2H). 
13
C NMR (125 MHz, CDCl3), (data 
for monomer): δ 15.92, 24.66, 41.46, 52.51, 56.67, 118.86. 
4.2.9 Synthesis of N-4,N-9-Dimethylspermine (22) 
 
     To a solution of 21 (3 g, 13.5 mmol) in ethanol (30 mL) was added Raney Nickel 
(approx. 10% w/w), followed by the addition of 50% aqueous sodium hydroxide (1.5 mL 
). The mixture was hydrogenated overnight in a Paar shaker apparatus at a pressure of 50 
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psi at room temperature. The mixture was filtered through a pad of celite and 
concentrated in vacuo to get the title compound as pale yellow oil (2.99 g, 96%). IR 
(Neat) νmax 3281, 2935, 2852, 2788, 1602, 1458, 1378, 1056 cm
-1
.
1
H NMR (500 MHz, 
CDCl3), (data for monomer): δ 1.46 (m, 2H), 1.64-1.57 (m, 2H), 2.2 (s, 2H), 2.46-2.33 
(m, 4H), 2.71 (t, 2H, J = 6.1), 3.42 (s, 3H). 
13
C NMR (125 MHz, CDCl3), (data for 
monomer): δ 25.10, 30.73, 40.38, 42.10, 55.49, 57.74. 
4.2.10 Synthesis of (2Z,2'Z)-N,N'-(3,3'-(butane-1,4-
diylbis(methylazanediyl))bis(propane-3,1-diyl))bis(2-(benzyloxyimino)-3-(3,5-
dibromo-4-methoxyphenyl)propanamide) (56) 
    
 
 
     To a solution of 22 (1 g, 4.3 mmol) in a mixture of CH2Cl2 (15 mL) and DMF (3 mL) 
at 0
o
C was added 2,6-lutidine (2 mL, 17.2 mmol) and after being stirred for 10 min, a 
solution of acid chloride 55 (6.2 g, 13 mmol) in CH2Cl2 (30 mL) was added dropwise. 
The reaction mixture was stirred for 6 h at room temperature, diluted with chloroform (50 
mL) and the organic layer was washed with H2O (25 mL), dried over Na2SO4 and 
evaporated under vacuum. The light yellow oil was chromatographed on silica column 
eluting with EtOAc:MeOH: NH4OH (6:4:1) to yield 56 as a thick yellow liquid (3.56 g, 
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75%). IR (Neat) νmax 2941, 2858, 2797, 1664, 1527, 1468, 1420, 1366, 1258, 1203, 996, 
906,726 cm
-1
. 
1
H NMR (500 MHz, CDCl3), (data for monomer): δ 1.43 (s, 2H, H-7), 1.66 
(m, 2H, H-3), 2.15 (s, 3H, N-CH3), 2.29 (br s, 2H, H-4), 2.40 (t, 2H, J = 4.88, H-6), 4.37 
(q, 2H, H-2), 3.83 (s, 5H, 4'-OMe, OCH2Ph), 5.20 (s, 2H, OCH2Ph), 7.36-7.27 (m, 5H, 
OCH2Ph), 7.44 (s, 2H, H-2', H-6'), 7.80 (br s, 1H, N-H). 
13
C NMR (125.7 MHz, CDCl3), 
(data for monomer): δ 24.96 (C-7), 26.00 (C-3), 28.72 (C-7'), 39.12 (C-2), 41.78 (4-N-
Me), 56.25 (C-4), 57.82 (C-6), 60.45 (4'-OMe), 77.33 (OCH2Ph), 117.62 (C-3', C-5'), 
127.92 (OCH2Ph), 128.24 (OCH2Ph), 128.57 (OCH2Ph), 133.43 (C-2', C-6'), 134.94 (C-
1'), 136.39 (OCH2Ph), 152.48 (C-8'), 151.52 (C-4'), 161.91 (C-9'’). 
4.2.11 Synthesis of Spermatinamine (3) 
 
     To a solution of 56 (0.2 g, 0.18 mmol ) in ethanol (10 mL) in a pressure vessel was 
added Pd-C (20 mg 10% wet basis) and the solution was subjected to hydrogenation in 
parr apparatus under the pressure of 40 psi for 0.5 h. The solution was filtered over a pad 
of celite, concentrated under vacuum and loaded over silica column eluting with 
MeOH:NH4OH (96:4) and then changing to (92:8) afforded the desired 3 as a white 
amorphous solid (0.087 g, 52%). mp: 170-172. IR (Neat) νmax 3441, 3021, 2901, 2766, 
1658, 1521, 1411, 1305, 1004, 730 cm
-1
. 
1
H NMR (500 MHz, DMSO-d6), (data for 
monomer): δ  1.61 (s, 2H, H-7), 1.80 (m, 2H, H-3), 2.70 (s, 3H, N-CH3), 3.02 (m, 2H, H-
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4), 3.08 (t, 2H, J = 4.88, H-6), 3.20 (q, 2H, H-2), 3.72 (s, 3H, 4'-OMe,), 3.75 (s, 2H, H-
7'), 7.45 (s, 2H, H-2', H-6'), 7.90 (br s, 1H, N-H). 
13
C NMR (125 MHz, DMSO-d6), (data 
for monomer): δ 21.96 (C-7), 23.50 (C-3), 25.72 (C-7'), 36.62 (C-2), 38.78 (4-N-Me), 
52.85 (C-4), 53.82 (C-6), 59.85 (4'-OMe), 117.52 (C-3', C-5'), 133.10 (C-2', C-6'), 134.98 
(C-1'), 150.28 (C-8'), 151.49 (C-4'), 162.01 (C-9'). 
4.2.12 Synthesis of 2,3-O-Isopropylidene-L-erythrose (34) 
 
 
      2,2-Dimethoxypropane (27 mL, 22.9 g, 0.220 mmol, 3.3 equiv) was added to a 
solution of L-arabinose 32 (10.0 g, 0.067 mol, 1.0 equiv) and p-toluenesulphonic acid 
monohydrate (150 mg, 0.8 mmol, 0.01 equiv) in dimethylformamide (130 mL). The 
resulting solution was stirred for 2 h, and then neutralized by solid sodium carbonate and 
concentrated under reduced pressure. The residue was partitioned between water (120 
mL) and 40 ± 60
o
C petroleum ether (60 mL). To the aqueous layer was then added 
sodium periodate (35.6 g, 0.166 mol, 2.5 equiv) portionwise, and the mixture was stirred 
for 2 h. Solid sodium carbonate was added and the slurry was stirred for 1 h. Water was 
then added (80 mL) and the aqueous layer was extracted with EtOAc (3 x 80 mL), and 
the combined organic extracts were concentrated under reduced pressure to yield a pale 
yellow oil. The crude product was purified by flash column chromatography on silica gel 
(EtOAc/hexane 7:13) to yield pure 34 (6.05 g, 57% from L-arabinose) as a mixture of 
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anomers (α:β 1:6): 1H NMR (400 MHz, CDCl3): δ = 1.36, 1.53 (2 s, 2 x 3H; C(CH3)2), 
2.09 (br s, 1H; OH), 3.53 (dd, 
2
J (H, H) = 11.1, 
3
J (H, H) = 3.7 Hz, 1H; CHH’), 3.96 (d, 2J 
(H, H) = 11.6 Hz, 1H; CHH’), 4.47 (dd, 3J (H, H) = 6.2, 3J (H, H) = 3.6 Hz, 1H; 
CH2CH), 4.74 (dd, 
3
J (H, H) = 6.2, 
3
J (H, H) = 3.7 Hz, 1H; CHOHCH), 4.98 (s, 1H; 
CHOH); 
13
C NMR (100 MHz, CDCl3 , DEPT): δ = 24.8, 25.9 (2 q, C(CH3)2), 67.5 (t, 
CH2), 78.2, 79.5 (2 d, 2 x CHO-), 97.4 (d, CHOH), 113.4 (s, C(CH3)2); β-anomer: 
1
H 
NMR (400 MHz, CDCl3): δ = 1.30, 1.45 (2 s, 3H; C(CH3)2), 3.61 (br s, 1H; OH), 3.99 (d, 
2
J (H, H) = 10.4 Hz, 1H; CHH’), 4.05 (dd, 2J( H, H) = 10.4, 3J (H, H) = 3.5 Hz, 1H; 
CHH’), 4.55 (d, 3J (H, H)=5.9 Hz, 1H; CHOHCH), 4.82 (dd, 3J (H, H) = 5.9, 3J (H, H = 
3.5 Hz, 1H; CH2CH), 5.39 (s, 1H; CHOH); 
13
C NMR (CDCl3 , 100 MHz): δ = 24.6, 26.1 
(2 q, 2 x C(CH3)), 71.8 (t, CH2), 79.9 (d, CH2CH), 85.1 (d, CHOHCH), 101.6 (d, 
CHOH), 112.2 (s, C(CH3)2); IR (film): v = 3426 cm
_1
 (br, O-H stretch), 2987, 2943, 2882 
(aliphatic C-H stretch), 1460; HRMS (CI): m/z: calcd for C7H16NO4 : 178.1083; found: 
178.1079 [M
+
+NH4]. 
4.2.13 2,3-O-Isopropylidene-erythritol (35)  
 
     To a solution of 34 (0.48 g, 3 mmol) in ethanol (20 mL) at 0 
0
C was added sodium 
borohydride (0.17, 4.5 mmol) and the reaction was stirred for 20 minutes at the same 
temperature, followed by stirring the solution for 1 hr at room temperature. The reaction 
mixture was neutralized with acetic acid and concentrated under reduced pressure, ethyl 
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acetate (35 mL) was added and washed with H2O (20 mL), brine (10 mL), dried over 
anhydrous Na2SO4, filtered and concentrated in a vacuum. The concentrate was purified 
by silica gel column chromatography using a mixture of hexane:ethyl acetate (6:4) and 
then changing to (1:1) afforded 35 as colorless thick oil (0.29 g, 60%).  
4.2.14 Synthesis of 4-(4-(benzyloxy)benzyl)-2-phenyloxazol-5(4H)-one (37) 
 
 
 
     A mixture of aldehyde 36 (3.00 g, 14 mmol), sodium acetate (1.4 g, 17.11 mmol), and 
hippuric acid (2.5 g, 14 mmol) in Ac2O (20 mL) was stirred at 120 °C for 3 h. A yellow 
solid was crushed out when the reaction mixture was cooled to room temperature. After 
filtration, the solid was washed with cold pentane:Et2O (8:2) to yield 37 as a yellow solid 
(3 g, 60%); mp: 143-145 
oC. IR (Neat) νmax 3260, 2897, 1783, 1761, 1703, 1650, 1593, 
1503, 1450, 1356, 1262, 1144, 980, 866, 808, 678 cm
-1
. 
1
H NMR (400 MHz, CDCl3): δ 
4.24 (s, 2H), 6.16 (d, 2H, J = 8.8), 6.30 (s, 1H), 6.54-6.41 (m, 5H), 6.62-6.58 (m,2H), 
6.69-6.66 (m, 1H), 7.28-7.24 (m, 4H). 
13
C NMR (100 MHz, CDCl3): δ 70.16, 115.40 
(2CH), 125.86, 126.80 , 127.47 (2CH), 128.17 (2CH), 128.23, 128.70 (2CH), 128.88 
(2CH), 131.25, 131.80, 132.99, 134.58 (2CH), 136.27, 161.36, 162.56, 167.95.  
4.2.15 Synthesis of 3-(4-(benzyloxy)phenyl)-2-oxopropanoic acid (38) 
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     A suspension of 37 (2 g, 5.6 mmol) in 20% NaOH (20 mL) was refluxed for 2 h. The 
mixture was cooled to room temperature and extracted with Et2O (50 mL). The aqueous 
layer was cooled on ice-bath and acidified to pH 4 with 2 M HCl and was extacted with 
EtOAc (50 mL x 2). The organic layer was washed with brine (20 mL), dried over 
Na2SO4 and evaporated under vacuum to give 38 as a pale yellow solid (1.0 g, 66%); mp: 
173-175 
oC. IR (Neat) νmax 3458, 3033, 2905, 2866, 1720, 1663, 1600, 1507, 1454, 1379, 
1233, 1173, 1110, 1011, 863, 737 cm
-1
. 
1
H NMR (400 MHz, DMSO): δ 5.09 (s, 2H), 6.38 
(s, 1H), 6.89 (d, 2H, J = 8.8), 7.44-7.31 (m,6H), 7.69 (d, 2H, J = 8.8). 
13
C NMR (125 
MHz, DMSO): δ 44.06, 69.22, 109.81, 114.75 (2CH), 127.85 (2CH), 128.48 (2CH), 
130.84 (2CH), 131.03, 137.03, 140.21, 157.59, 166.59.   
4.2.16 Synthesis of (Z)-3-(4-(benzyloxy)phenyl)-2-(benzyloxyimino)propanoic acid 
(39) 
 
 
      To a mixture of compound 38 (1 g, 3.7 mmol) and N-benzyloxylamine hydrochloride 
(0.65 g, 4.1 mmol) in dioxane (20 mL ) was added sodium hydrogen carbonate (1.1 g, 13 
mmol) and the mixture was stirred at 40 
o
C for 5 h. The reaction was concentrated under 
reduced pressure, diluted with ethyl acetate (50 mL) and washed with H2O (20 mL), brine 
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(10 mL), dried over anhydrous Na2SO4, filtered and concentrated in a vacuum. The 
column chromatography purifications of the yellow oily material, eluting with ethyl 
acetate:hexanes (1:1) and then changing to (8:2) yielded the tile compound 38 as a light 
yellow solid (0.67 g, 48%). mp: 91-92 
o
C. IR (neat)
 
3310, 3031, 1703, 1609, 1509, 1451, 
1317, 1004, 984, 918, 757, 696 cm
–1
. 
1
H NMR (CDCl3, 500 MHz) δ: 3.86 (2H, s, H-1'), 
5.02 (2H s, OCH2Ph), 5.30 (2H, s, OCH2Ph), 6.86 (2H, d, J = 8.5 Hz, H-2, H-6), 7.18 
(2H, d, J = 8.5 Hz, H-3, H-5), 7.42-7.32 (10H, m, OCH2Ph). 
13
C NMR (125.7 MHz, 
CDCl3) δ: 29.5 (C-1'), 70.0 (OCH2Ph), 78.3 (OCH2Ph), 114.9 (C-2, C-6), 127.2(C-3, C-
5), 127.4 (OCH2Ph), 127.9 (OCH2Ph), 128.3 (OCH2Ph), 128.5 (OCH2Ph), 128.6 
(OCH2Ph), 130.4 (OCH2Ph), 135.8 (OCH2Ph), 137.0 (OCH2Ph), 150.3 (C-2'), 157.7 (C-
1), 162.6 (CO2H). Anal. Calcd for  C23H21NO4: C 73.58, H 5.64, N 3.73. Found C 73.54, 
H 5.70, N 3.70. 
4.2.17 Synthesis of (2Z,2Z')-((4R,5S)-2,2-dimethyl-1,3-dioxolane-4,5-
diyl)bis(methylene) bis(3-(4-(benzyloxy)phenyl)-2-(benzyloxyimino) 
propanoate) (40) 
 
 
 
     To a solution of mixture of oxime 39 (1.0 g, 2.66 mmol) and erythritol 35 (0.2 g, 1.21 
mmol) in CH2Cl2 (20 mL) at 0 
o
C was added dicyclohexylcarbodiimide  (0.6 g, 2.91 
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mmol), followed by the addition of 4-(Dimethyamino)pyridine (0.032 g, 0.27 mmol) and 
the reaction mixture was aged for 1.5 h at the same temperature, cold water (20 mL) and 
Et2O (50 mL) were added and the organic layer was separated, cooled on ice bath and the 
solid was filtered. The organic layer was dried over anhydrous Na2SO4, filtered and 
evaporated under vacuum. Column chromatography over silica gel of the greenish oily 
material eluting with hexane:ethyl acetate (85:15) and then changing to (8:2) yielded the 
desired 40 (0.74 g, 70%) as a light green gum. IR (neat) 3031, 2930, 1723, 1609, 1509, 
1453, 1372, 1241, 1195, 1123, 736, 697 cm
–1
. 
1
H NMR (CDCl3, 500 MHz) δ: 1.34 (3H, 
s, C(CH3)2), 1.38 (3H, s, C(CH3)2), 3.83 (4H, s, H-3', H-3"), 4.28 (2H, s, H-2, H-3), 4.37 
(4H, m, H-1, H-4), 4.98 (4H, s, OCH2Ph), 5.29 (4H, s, OCH2Ph), 6.81 (4H, d, J = 8.5 Hz, 
H-6', H-8', H-6", H-8"), 7.13 (4H, d, J = 8.5 Hz, H-5', H-9', H-5", H-9"), 7.40-7.32 (20H, 
m, OCH2Ph). 
13
C NMR (125.7 MHz, CDCl3) δ: 25.3 C(CH3)2), 27.6 C(CH3)2), 30.5 (C-
3', C-3"), 69.4 (C-1, C-4), 69.9 (OCH2Ph), 74.5 (C-2/C-3), 74.8 (C-2/C-3), 77.8 
(OCH2Ph), 109.5 (C(CH3)2), 114.7 (C-6', C-6" C-8', C-8"), 127.4 (C-5', C-5" C-9', C-9"), 
128.0 (OCH2Ph), 127.9 (OCH2Ph), 128.2 (OCH2Ph), 128.3 (OCH2Ph), 128.4 (OCH2Ph), 
128.5 (OCH2Ph), 130.2 (OCH2Ph), 136.5 (OCH2Ph), 137.0 (OCH2Ph), 150.5 (C-2', C-
2"), 157.5 (C-7', C-7"), 163.0 (C-1', C-1"). Anal. Calcd for C53H52N2O10: C 72.59, H 
5.98, N 3.19. Found C 72.55, H 6.04, N 3.15. 
1
H     
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4.2.18  Synthesis of (2Z,2Z')-((2R,3S)-2,3-dihydroxy-butane-1,4-diyl) bis(3-(4-
(benzyloxy)phenyl)-2-(benzyloxyimino)propanoate) (41)  
 
 
     To a solution of compound 40 (0.3 g, 0.34 mmol) in a mixture of THF and H2O (2:1, 6 
mL) at 0 
o
C was added trifluoroacetic acid (1.5 mL) and the reaction mixture was stirred 
at room temperature for 72 h, ethyl acetate (20 mL) was added and the organic layer was 
separated, washed with sat. NaHCO3 (15 mL), brine (10 mL), dried over anhydrous 
Na2SO4, filtered and evaporated. The colorless thick oil was resolved over silica column, 
eluting with hexane:ethyl acetate (6:4) and then changing to (1:1) produced the desired 
41 as a white amorphous solid (0.25 g, 88%). MP: 101-102 
o
C.
 
IR (neat) 3370, 3040, 
1720, 1610, 1502, 1460, 1375, 1230, 736, 690 cm
–1
.
 1
H NMR (500 MHz, CDCl3) δ: 2.65 
(br. s, 2H, OH), 3.78 (m, 2H, H-2, H-3), 3.86 (s, 4H, H-3', H-3"), 4.38-4.34 (m, 4H, H-1, 
H-4), 5.00 (s, 4H, OCH2Ph), 5.29 (s, 4H, OCH2Ph), 6.84 (d, 4H, J = 8.5 Hz, H-6', H-8', 
H-6", H-8"), 7.13 (d, 4H, J = 8.5 Hz, H-5', H-9', H-5", H-9"), 7.40-7.33 (m, 20H, 
OCH2Ph). 
13
C NMR (125.7 MHz, CDCl3) δ: 30.5 (C-3', C-3"), 66.8 (C-1, C-4), 70.0 (C-
2, C-3), 70.1 (OCH2Ph), 77.9 (OCH2Ph), 114.9 (C-6', C-6" C-8', C-8"), 127.4 (C-5', C-5" 
C-9', C-9"), 127.9 (OCH2Ph), 128.3 (OCH2Ph), 128.4 (OCH2Ph), 128.5 (OCH2Ph), 
128.6 (OCH2Ph), 130.1 (OCH2Ph), 136.3 (OCH2Ph), 137.0 (OCH2Ph), 150.8 (C-2', C-
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2"), 157.6 (C-7', C-7"), 163.5 (C-1', C-1"). Anal. Calcd for C50H48N2O10: C 71.76, H 
5.78, N 3.35. Found C 71.70, H 5.82, N 3.30. 
4.2.19 Synthesis of Aspergillusol A (19)  
 
 
 
     To a solution of 41 (0.15 g, 0.18 mmol) in a mixture of THF and ethanol (1:1, 10 mL) 
in a pressure vessel was added Pd-C (10% wet basis, 0.05 g) and the solution was 
subjected to hydrogenation in parr apparatus under the pressure of 50 psi for 3 h. The 
solution was filtered over a pad of celite, concentrated under vacuum and loaded over 
silica column eluting with CH2Cl2:MeOH (95:5) and then changing to (92:8) afforded the 
desired 19 as a light yellow amorphous solid (0.051 g, 60%). All the spectral data of 19 
coincided with those of literature reported values.
65
 NMR (500 MHz, DMSO-d6) δ: 3.65 
((m, 2H, H-2, H-3), 3.70 (s, 4H, H-3', H-3"), 4.10 (dd, 2H, J = 5.3, 11.1 Hz, H-1, H-4), 
4.29 (br d, 2H, J = 10.8 Hz, H-1, H-4), 5.14 (br d, 2H, J = 5.2 Hz, 2-OH, 3-OH), 6.62 
(4H, d,  J = 8.5 Hz, H-6', H-8', H-6", H-8"), 7.00 (4H, d, J = 8.5 Hz, H-5', H-9', H-5", H-
9"), 9.21 (s, 2H, Ar- OH), 12.38 (s, 2H, N-OH). 
13
C NMR (125.7 MHz, DMSO-d6) δ: 
29.6 (C-3', C-3"), 67.1 (C-1, C-4), 69.4 (C-2/C-3),  115.5 (C-6', C-6" C-8', C-8"), 126.8 
(C-4′, C-4′′), 130.1 (C-5', C-5" C-9', C-9"), 150.5 (C-2′, C-2′′), 156.1 (C-7′, C-7′′), 164.2 
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(C-1′, C-1′′). Anal. Calcd for  C22H24N2O10: C 55.46, H 5.08, N 5.88. Found C 55.43, H 
5.10, N 5.85. 
4.2.20 Synthesis of 1-(2,4-dihydroxyphenyl)ethanone (43) 
 
 
 
     A mixture of resorcinol 42 (17.6 g, 160 mmol) and ZnCl2 (22.4 g, 164 mmol) in acetic 
acid (50 mL) was refluxed for 5 h. The reaction mixture was cooled to ~ 40
o
C, poured on 
ice cold water (500 mL) and solid was filtered. Recrystallization from water gave 43 as 
reddish needles (16.5 g, 67%). 
1
H NMR (100 MHz, CDCl3:CD3OD): δ 2.51 (s, 3H), 3.10 
(br s, 2H), 6.36 (s, 1H), 6.38 (d, 1H, J = 8.8), 7.58 (d, 1H, J = 8.8). 
13
C NMR (400 MHz, 
CDCl3:CD3OD): δ 26.00, 102.96, 108.29, 113.39, 132.98, 164.61(2C), 202.72. 
4.2.21 Synthesis of 1-(4-(allyloxy)-2-hydroxyphenyl)ethanone (45) 
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      To a solution of 43 (10.6 g, 70 mmol) in acetone (100 mL) was added K2CO3 (20 g, 
146 mmol) and the reaction was stirred for 10 min at room temperature, followed by the 
addition of allyl bromide (6.6 mL, 76.6 mmol) and the reaction mixture was stirred for 7 
h at 40 
o
C. The solvent was evaporated under vacuum, diluted with ether (150 mL) and 
washed with 2N NaOH (50 mL x 2). The white solid formed was collected through 
filtration and added to combined aqueous layers and acidified to pH ~ 4 with 20% HCl 
while cooling on ice-bath. The aqueous layer was then extracted with EtOAc (100 mL x 
2) and the combined organic layers were washed with brine, dried over anhydrous 
sodium sulfate and evaporated in vacuo to yield 45 as a thick brown liquid (12.5 g, 93%). 
1
H NMR (500 MHz, CDCl3): δ 2.60 (s, 3H), 4.57 (d, 2H, J = 4.9), 5.33 (d, 2H, J = 8.55), 
5.44 (d, 1H, J = 17.1), 6.03 (m, 1H), 6.42 (s, 1H), 6.45 (m, 1H), 7.64 (d, 1H, J = 5.3), 
12.72 (s, 1H). 
13
C NMR (125 MHz, CDCl3): δ 26.17, 68.92, 101.63, 107.99, 113.96, 
118.35, 132.14, 132.27, 165.11 (2CH), 202.55.  
4.2.22 Synthesis of 1-(3-allyl-2,4-dihydroxyphenyl)ethanone (46) 
 
 
 
     To a solution of 45 (5 g, 26 mmol) in N,N’dimethylaniline (7 mL) was bubbled N2 for 
5 min and the mixture was refluxed for 2 h. The reaction was cooled to room 
temperature, EtOAc (50 mL) was added and washed with 10% HCl (100 mL x 2). The 
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combined organic layer was washed with brine, dried over anhydrous sodium sulfate and 
evaporated under vacuum to give a dark brown oily residue which was purified by silica 
gel column, eluting with EtOAc:hexane (1:9) to yield 46 as a pale yellow solid (2.7 g, 
54%); mp: 110-115 
oC. IR (Neat) νmax 3120, 2040, 1613, 1491, 1423, 1369, 1313, 1264, 
1106, 1033, 914 cm
-1
. 
1
H NMR (500 MHz, CDCl3): δ 2.60 (s, 3H), 3.53 (d, 2H, J = 6.1), 
5.19 (t, 2H), 5.90 (s, 1H), 6.03 (m, 1H), 6.45 (d, 1H, J = 8.85), 7.61 (d, 1H, J = 8.5). 
13
C 
NMR (125.7 MHz, CDCl3): δ 26.17, 26.64, 107.63, 112.57, 113.92, 116.06, 130.69, 
135.48, 161.21, 162.75, 202.95. 
4.2.23 Synthesis of methyl 4-hydroxybenzoate (50) 
 
     To a solution of 4-hydroxy benzoic acid (2 g, 14.4 mmol) in CH3OH (50 mL) was 
added conc. H2SO4 (2 mL) and the reaction mixture was refluxed overnight. The excess 
methanol was evaporated off and the reaction mixture was poured onto ice cold water. 
Methyl-4-hydroxy benzoate was isolated as a white powder (1.1 g, 50%). IR (KBr) nmax: 
3311, 1682, 1607, 1588, 1514, 1434, 1314, 1279, 1164, 849, 771 cm
-1
. 
1
H NMR (500 
MHz): δ 3.822 (s, 3H), 6.908-6.926 (d, 2H), 7.877-7.894 (d, 2H), 13C NMR (125.7 MHz, 
CDCl3): δ 52.09, 115.34, 121.97, 131.94, 160.65, 167.57.  
4.2.24 Synthesis of 4-acetyl-2-allyl-3-hydroxyphenyl benzoate (59) 
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                 To a solution of 46 (2 g, 10.40 mmol) in dichloromethane (30 mL) at 0 
o
C was added 
Et3N (2.1 20.8 mmol), followed by the dropwise addition of benzoyl chloride (2.1 g, 
13.52 mmol) and the stirring was continued at 0
o
C for 30 minutes and then for 2 h at 
room temperature. Water (20 mL) was added and the organic layer was separated and 
washed with brine, dried over Na2SO4 and concentrated under vacuum to give 59 as an 
orange thick liquid (3.02 g, 98%). IR (Neat) νmax 3075, 3005, 2922, 1725, 1615, 1500, 
1411, 1365, 1230, 11180, 1069, 1020, 988, 912 cm
-1
. 
1
H NMR (500 MHz, CDCl3): δ 2.65 
(s, 3H), 3.43 (d, 2H, J = 6.1), 4.98 (m, 2H), 5.90 (m, 1H), 6.80 (d, 1H, J = 8.55), 7.53 (t, 
2H, J = 7.79), 7.67 (t, 1H, J = 7.60), 7.71 (d, 1H, J = 8.85), (d, 1H, J = 8.85), 8.20, (dd, 
2H, J = 8.2, 1.2). 
13
C NMR (125.7 MHz, CDCl3): δ 26.74, 27.72, 113.49, 115.51, 117.43, 
121.45, 128.71 (2CH), 128.93, 129.38, 130.22 (2CH), 133.93, 134.73, 155.03, 162.25, 
164.33, 203.90. 
4.2.25 Synthesis of 4-acetyl-2-allyl-3-methoxyphenyl benzoate (60) 
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     To a solution of 59 (3.0 g, 9.7 mmol) in DMF (30 mL) at 0 
o
C was added K2CO3 (2.67 
g, 19.3 mmol) and the mixture was stirred for 15 min at room temperature and then 
cooled to 0 
o
C. Iodomethane (2.1 g, 14.55 mmol) was added drop wise to the mixture at 0
 
C and the reaction was stirred overnight at room temperature. The reaction was diluted 
with H2O (20 mL) and EtOAc (50 mL) and washed with 10% HCl (20 mL), brine (15 mL 
x 2), dried over anhydrous sodium sulfate and evaporated under vacuum to yield 60 as a 
yellow solid (2.89 g, 96%). mp 54-55 
o
C. IR (Neat) νmax 3740, 3073, 2938, 1736, 1679, 
1445, 1404, 1360, 1236, 1167, 1067, 1026, 917 cm
-1
. 
1
H NMR (500 MHz, CDCl3): δ 2.65 
(s, 3H), 3.46 (d, 2H, J = 7.00), 3.80 (s, 3H), 5.00 (m, 2H), 3.92 (m, 1H), 7.08 (d, 1H, J = 
8.55), 7.53 (t, 2H), 7.62 (t, 1H), 7.66 (t, 1H), 8.18 (d, 2H, J = 8.55). 
13
C NMR (125.7 
MHz, CDCl3): δ 28.65, 30.18, 63.46, 114.79, 115.85, 118.74, 126.89, 128.57 (2CH), 
128.68, 129.83 (2CH), 130.18, 131.17, 133.86, 135.38, 153.10, 158.93, 164.45. 
4.2.26 Synthesis of 1-(3-allyl-2-hydroxy-4-(4-methoxybenzyloxy)phenyl)ethanone 
(64) 
 
 
 
     To a solution of 46 (2 g, 10.42 mmol) in acetone (20 mL) was added K2CO3 (2.87 g, 
20.8 mmol) and after being stirred for 10 min at room temperature, 4-methoxybenzyl 
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chloride ( 1.74 g, 1.48 mL, 10.94 mmol) was added and the mixture was heated at 60
o
C 
for 4 h. The solvent was evaporated under vacuum and the crude product was purified by 
silica column chromatography, eluting with EtOAc:hexane (1:20) and then changing to 
(2:10) yielded 64 as a white solid (3.1 g, 95%). IR (Neat) νmax 2922, 2836, 1614, 1505, 
1420, 1368, 1238, 1175, 1119, 1062, 908, 816, 726, 632 cm
-1
. 
1
H NMR (500 MHz, 
CDCl3): δ 2.53 (s, 3H), 3.55 (d, 2H, J = 6.1), 3.80 (s, 3H), 4.97 (m, 2H), 5.07 (s, 2H), 
5.96 (m, 1H), 6.50 (d, 1H, J = 8.50), 6.90 (d, 2H, J = 8.55), 7.32 (d, 2H, J = 8.55), 7.58 
(d, 1H, J = 9.75), 12.78 (s, 1H). 
13
C NMR (125.7 MHz, CDCl3): δ 26.23, 26.80, 55.29, 
70.03, 103.43, 114.04 (2CH), 114.41, 114.68, 115.93, 128.49, 128.76 (2CH). 130.12, 
130.55, 135.89, 159.51, 161.99, 162.53. 
4.2.27 1-(3-allyl-2-methoxy-4-(4-methoxybenzyloxy)phenyl)ethanone (65) 
 
 
 
     To a solution of 64 (1.3 g, 4.2 mmol) in DMF (15 mL) was added K2CO3 (1 g, 7.08 
mmol) and the mixture was stirred for 15 min at room temperature and then cooled to 0 
o
C. Iodomethane (8.4 mmol, 0.5 mL) was added dropwise to the reaction and the mixture 
was stirred overnight at room temperature. To the reaction was added H2O (20 mL), 
EtOAc (15 mL) and washed with 10% HCl, brine (10 mL x 2), dried over anhydrous 
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sodium sulfate and the solvent evaporated in vacuo to yield 65 as a yellow thick liquid 
(1.3 g, 95%). 
1
H NMR (500 MHz, CDCl3): δ 2.27 (s, 3H), 3.48 (d, 2H, J = 6.1), 3.76 (s, 
3H), 3.82 (s, 3H), 5.00 (m, 4H), 5.97 (m, 1H), 6.76 (d, 1H, J = 8.5), 6,91 (d, 2H, J = 
8.55), 7.33 (d, 2H, J = 8.55), 7.60 (d, 1H, J = 8.55). 
13
C NMR (125.7 MHz, CDCl3): δ 
28.07, 29.92, 55.21, 63.02, 70.03, 107.36, 113.91 (2CH), 114.92 (2CH), 122.56, 125.93, 
128.45, 128.75 (2CH), 129.70, 136.44, 159.38, 160.96, 162.46, 199.00.  
4.2.28 Synthesis of methyl 4-(4-methoxybenzyloxy)benzoate (66) 
 
 
 
     To a solution of 50 (2 g, 13.14 mmol) in DMF was added K2CO3 (3.63 g, 26.3 mmol) 
and after being stirred for 10 min at room temperature, 4-methoxybenzyl chloride (2.67 g, 
17.1 mmol) was added and the stirring was continued at room temperature for 3 h. The 
reaction was diluted with EtOAc (30 mL) and washed with H2O (20 mL), 10% HCl (15 
mL), brine (15 mL x 2), dried over anhydrous sodium sulfate and evaporated under 
vacuum to yield 66 as a white solid (3.50 g, 98%). 
1
H NMR (500 MHz, CDCl3): δ 3.82 
(s, 3H), 3.88 (s, 3H), 5.03 (s, 2H), 6.91 (m, 4H), 7.36 (d, 2H, J = 8.55), 8.00 (d, 2H, J = 
9.75). 
13
C NMR (125.7 MHz, CDCl3): δ 51.85, 55.31, 69.93, 114.11(2CH), 114.48 
(2CH), 122.74, 128.28, 129.41(2CH), 131.59 (2CH), 159.65, 162.59, 166.86. 
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4.2.29 Synthesis of 7-(allyloxy)-4-hydroxy-2H-chromen-2-one (73) 
 
 
     A solution of 45 (35.8 g, 0.186 mol) in dry benzene (400 mL) was added with stirring 
to a suspension of NaH (10.4 g, 0.43 mol) in dry benzene (400 mL) over 30 min at reflux. 
After being stirred for 10 min, a solution of diethyl carbonate (46.4 g, 0.38 mmol) in dry 
PhH (400 mL) was added over 1 h, and the mixture was refluxed overnight. The reaction 
was cooled to room temperature and the mixture was poured onto ice-cold 2 N HCI (2 L), 
and the solid formed was filtered, and recrystallized from EtOH to give 30.5 g (75%) of 
73; mp: 235-236 
o
C. 
1
H NMR (125.7 MHz, CD3OD): δ 4.65 (d, 2H, J = 4.8), 5.29 (d, 1H, 
J = 10.4), 5.48 (t, 2H), 6.03 (m, 1H), 6.92 (s, 2H), 7.70 (d, 1H J = 8). 
13
C NMR (400 
MHz, CD3OD): δ 69.13, 88.83, 101.60, 109.37, 112.73, 118.46, 124.75, 133.26, 155.62, 
162.14, 162.82, 166.44. 
4.2.30 Synthesis of 7-(allyloxy)-4-methoxy-2H-chromen-2-one (77) 
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     To a solution of 73 (5 g, 23 mmol) in acetone (50 mL) was added K2CO3 (3.8 g, 27.5 
mmol) and the reaction was stirred at room temperature for 15 min. Dimethyl sulfate (3.5 
g, 25.5 mmol) was added to the mixture and stirred at 50
o
C for 2 h. The solid was filtered 
and the solvent was evaporated under vacuum to yield 77 as a white solid (4.25 g, 80%); 
mp: 70-73 
o
C. IR (Neat) νmax 3395, 3235, 3072, 2839, 2099, 1920, 1736, 1605, 1434, 
1393, 1246, 1148, 1091, 1005, 968, 813, 572, 474 cm
-1
.
 1
H NMR (400 MHz, CD3OD): δ 
3.92 (s, 3H), 4.55 (d, 2H, J = 8.00), 5.30-5.27 (m, 1H), 5.41-5.36 (m, 1H), 5.51 (s, 1H), 
6.02-5.96 (m, 1H), 6.81-6.75 (m, 2H), 7.65 (d, 1H, J= 8.8). 
13
C NMR (125.7 MHz, 
CD3OD): δ 56.20, 69.21, 87.66, 101.35, 109.0, 112.68, 118.46, 124.04, 132.18, 155.02, 
162.16, 163.37, 166.80. 
4.2.31 Synthesis of 8-allyl-7-hydroxy-4-methoxy-2H-chromen-2-one (78) 
 
     A solution of 77 (3 g, 12.9 mmol) in decalin (5 mL) was refluxed under N2 for 3 h, 
and the mixture was cooled to room temperature. The solid formed was filtered to get the 
title compound as a yellow solid (1.86 g, 62%); mp: 230-233 
o
C. IR (Neat) νmax 3086, 
2193, 1686, 1603, 1570, 1508, 1437, 1385, 1311, 1231, 1108, 1050, 1011, 905, 803, 734 
cm
-1
.H NMR (400 MHz, CDCl3:CD3OD): δ 3.52 (d, 2H , J = 7.6), 3.89 (s, 3H), 4.96 (m, 
2H), 5.47 (s, 1H), 5.91 (m, 1H), 6.72 (d, 1H, J = 8.8), 7.46 (d, 1H, J = 8.8). 
13
C NMR 
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(125.7 MHz, CDCl3:CD3OD): δ 26.81, 56.08, 86.43, 108.01, 112.04, 113.65, 115.00, 
121.46, 135.08, 152.66, 159.12, 164.68, 167.75. 
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